source
- Former Spark co-founder Steven Altschuler launches new immune-resetting biotechSteven Altschuler, who co-founded Spark Therapeutics, has announced the formation of a new biotech that aims to reset the immune system. The venture is positioned to address autoimmune diseases, a…
- Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinomaHighlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…